Prostate cancer (CaP) is mostly composed of luminal-like differentiated cells, but contains a small subpopulation of basal cells (including stem-like cells), which can proliferate and differentiate into luminal-like cells. In cancers, CpG island hypermethylation has been associated with gene downregulation, but the causal relationship between the two phenomena is still debated. Here we clarify the origin and function of CpG island hypermethylation in CaP, in the context of a cancer cell hierarchy and epithelial differentiation, by analysis of separated basal and luminal cells from cancers. For a set of genes (including GSTP1) that are hypermethylated in CaP, gene downregulation is the result of cell differentiation and is not cancer specific. Hypermethylation is however seen in more differentiated cancer cells and is promoted by hyperproliferation. These genes are maintained as actively expressed and methylation-free in undifferentiated CaP cells, and their hypermethylation is not essential for either tumour development or expansion. We present evidence for the causes and the dynamics of CpG island hypermethylation in CaP, showing that, for a specific set of genes, promoter methylation is downstream of gene downregulation and is not a driver of gene repression, while gene repression is a result of tissue-specific differentiation.
It is likely that cancer originates from environmental, genetic and epigenetic perturbation of tissue stem or progenitor cells. 1, 2 The end result of these aberrations is a cancer mass possessing a cellular hierarchy which mirrors that in normal tissue. 3 Accumulating evidence now shows just such a hierarchical structure in many cancers 4 including prostate. 5 In particular, prostate cancer (CaP) is characterized by an imbalance of the differentiation process, resulting in the accumulation of proliferative differentiated luminal cancer cells (composing 499% of the tumour). [6] [7] [8] A small population of basal cells (o1% of cells), which shares chromosomal changes such as a TMPRSS2-ERG fusion with the luminal cancer cells, 9 still persists in CaP. Although the field is still debating on the origin and phenotype of prostate cancer stem cells, [10] [11] [12] [13] several lines of evidence show that they might indeed reside within this small population of basal cells. 5, [12] [13] [14] Aberrant DNA methylation patterns are found in all cancers, and hypermethylation of CpG islands in promoter regions has been associated with cancer-specific gene downregulation, promoting both cancer development and progression. 15 However, it is unclear whether hypermethylation causes gene downregulation 16 or simply maintains it, by adding a final 'lock' on the promoter, whereas the initial gene downregulation is carried out by DNA methylation-independent mechanisms. 17, 18 CaP is characterized by hypermethylation of numerous promoters, 19 but also an unexpectedly high intrapatient variability, where each individual develops a unique DNA methylation signature. 20 Of the genes hypermethylated in CaP, GSTP1 is the best studied. 21 It encodes a detoxifying enzyme, which is able to protect cells from DNA adduct formation by electrophilic compounds. 22 GSTP1 hypermethylation is already present in preneoplastic lesions such as prostatic intraepithelial neoplasia (PIN), 23 promoting the hypothesis that epigenetic downregulation of GSTP1 sensitizes cancer precursor cells (cell of origin) to carcinogenic insults and promotes tumour progression. 24 However, the causes of GSTP1 downregulation and hypermethylation in CaP are still unknown.
This study aimed to understand the function and origin of CpG island hypermethylation in CaP, in the context of cancer hierarchy and differentiation. We report that a set of genes commonly hypermethylated in CaP (including GSTP1) is (i) downregulated as a result of prostate-specific epithelial differentiation in both CaP and benign prostatic hyperplasia (BPH); (ii) selectively hypermethylated only in differentiated (luminal) cells, most likely promoted by their hyperproliferative phenotype; (iii) actively expressed and methylation free in undifferentiated (basal) CaP cells. Downregulation and hypermethylation of these genes is however not essential for tumour development or tumour expansion. Moreover, for all these genes, the downregulation induced by prostate-specific differentiation is independent of DNA hypermethylation and is associated with detachment of RNAPolII from their promoters and a reduction in histone marks associated with active transcription.
Results
GSTP1 is downregulated through epithelial differentiation and hypermethylated only in CaP luminal cells. GSTP1 promoter methylation was quantified by pyrosequencing in a panel of CaP cell lines (Figure 1a ) spanning the entire spectrum of epithelial differentiation from basal to luminal. In agreement with previous reports, 25 high levels of DNA methylation (490%) were found in luminal CaP cell lines (LnCaP, PC346C and VCaP), whereas no methylation (RC-165N/hTERT, PNT1A, PNT2-C2) or little methylation (BPH-1) was found in benign cell lines. Cancer cell lines with an intermediate differentiation phenotype (PC3, DU145) 26 showed partial methylation (50-60%). Strikingly, no methylation was found in cancer-derived cell lines with a basal phenotype (P4E6, Bob and SerBob). 27, 28 We then analysed GSTP1 methylation and expression levels in separated basal and luminal cells isolated from BPH and CaP tissues. Lin À /CD31 À /CD24 þ luminal cells were isolated from disaggregated prostate primary tissues (Supplementary Figure 1) . As a source of basal cells, primary prostate epithelial cultures were generated as previously described 5, 29, 30 from fresh BPH and CaP tissues. Cultures from CaP tissues still retain cancer features: (i) increased invasion capacity and (ii) proliferative potential, 5 genomic rearrangements such as (iii) TMPRSS2-ERG fusion 5,9,29 and (iv) microsatellite instability, 5 (v) high telomerase expression and activity (Rane et al, in preparation), (vi) overexpression of cancer-associated genes (eg, AMACR and MMP9) and downregulation of PTEN. 29 We have confirmed the cells' phenotype by immunofluorescence and qRT-PCR: Supplementary  Figures 2 and 3A (Figure 1b) . Strikingly, CaP basal cells showed no GSTP1 hypermethylation.
GSTP1 mRNA levels ( Figure 1c ) were high in both BPH and CaP basal cells, with a significant downregulation in luminal cells and no significant difference between BPH and CaP. High expression in CaP basal cells was confirmed by the reanalysis of our previous microarray data 29 (Supplementary Figure 4) .
As an alternative source for undifferentiated CaP cells, we utilised 'near-patient' xenografts generated in BALB/c/ RAG2
À / À gC À / À mice. 31 Xenografts mainly show an intermediate phenotype co-expressing basal and luminal markers, with less than 5% of partially differentiated cells (CD24 þ / AR low ). Compared with P4E6 (basal) and LNCaP (luminal), all the xenografts analysed actively expressed GSTP1, with small variations between samples (Figure 1d) . Moreover, none of the xenografts showed hypermethylation of GSTP1 either as an unfractionated tissue (Figure 1e , left) or as fractionated cell populations representing heterogeneous (Figure 1e , central). For one xenograft (H027/10), we confirmed that hypermethylation of GSTP1 was present in the original tumour tissue but lost upon grafting (Figure 1e, right) . Altogether these results show that GSTP1 is not hypermethylated and is highly expressed in undifferentiated basal-like cancer cells.
GSTP1 methylation correlates with the differentiation status of hyperproliferating prostate epithelial cells. The previous results strongly indicated that GSTP1 is hypermethylated only in luminal CaP cells. As these cells are highly proliferative compared with their normal counterparts, 32 significantly upregulate DNMT3A compared with basal cells (Supplementary Figures 3C-F) and DNA methyltransferases are mostly active in the S phase of the cell cycle, 33 we hypothesized that a combination of cell differentiation, high DNMTs and hyperproliferation could be the primary cause of GSTP1 hypermethylation in CaP. To test this, we dissected GSTP1 hypermethylation heterogeneity in BPH-1 cells: an established cell model for hyperproliferating prostate cells with an intermediate phenotype.
BPH-1 cells 34 Figure 6) , indicating GSTP1 upregulation in more undifferentiated cells. To dissect BPH-1 heterogeneity, eighteen clones were derived from single BPH-1 cells. These clones show extreme variability in GSTP1 mRNA levels, protein expression (Figures 2a and d ) and promoter methylation (Figure 2b) , with a strong inverse correlation between expression and methylation ( Figure 2c ). Taken altogether, these results suggest that GSTP1 expression and methylation are strictly correlated and linked to the cells' differentiation state.
To directly confirm this link, more BPH-1 clones were derived, colonies were fixed after 7 days' growth, and costained for GSTP1 and Cytokeratin5 (Figure 2e ). Colonies with an overall overexpression or downregulation of both markers were identified (exemplified in Figure 2e ). Methylation analysis Origin of DNA hypermethylation in prostate cancer D Pellacani et al performed on the same cells after immunofluorescence revealed that colonies with low levels of GSTP1 and Cytokeratin5 also hypermethylated GSTP1, compared with colonies with high levels of both proteins (Figure 2f ). This confirmed that, in a hyperproliferating system, GSTP1 hypermethylation is present preferentially in differentiated cells. genes hypermethylated in CaP. We generated a comprehensive list of promoters hypermethylated in CaP from publicly available resources and assessed gene expression in three data sets: CaP versus normal prostate tissues, 35 luminal versus basal primary prostate cells, 36 CaP versus BPHderived basal cells. 29 As expected, 'genes hypermethylated in We then generated a list of genes highly expressed in prostate basal cells from BPH and CaP 29 and intersected it with the list of genes hypermethylated in CaP, finding 206 genes that are potentially regulated similarly to GSTP1 (Figure 3a and Supplementary Table 1) . We named these genes 'Differentiation-Associated Hypermethylated' (DAH). Expression analysis of DAH genes in the same data sets 35, 36 revealed that they are strongly enriched for genes downregulated in CaP tissues, and also in normal luminal cells (Figures 3b and c) , supporting the hypothesis that these genes are, like GSTP1, mainly downregulated during differentiation and subsequently hypermethylated in CaP.
As hypermethylation in cancer has been associated with areas marked by bivalent chromatin in embryonic stem cells (ESCs), 37 we interrogated the ENCODE database for the presence of H3K4me3 and H3K27me3 on the promoters of DAH genes in H1-hESCs 38 ( Figure 3d ). More than 40% of DAH genes were marked by both H3K4me3 and H3K27me3, indicative of bivalent chromatin. However, almost half of DAH genes were marked only by H3K4me3, whereas a very small proportion of genes was marked by H3K27me3. This suggested that DAH genes are either in an active or in poised state in ESCs, are then maintained as active or activated in prostate stem cells (high expression) and repressed during prostate specific differentiation.
We also checked the frequency of hypermethylation of the DAH promoters in CaP (Kobayashi et al. 39 data set). The results indicated a wide variation ranging from high (74%) to very low (1%) (Supplementary Figure 7D) . Thus, downregulation in hyperproliferating luminal cells may not always be sufficient to cause consistent gene hypermethylation.
We then selected seven representative DAH genes for further analysis, through two independent processes (Figure 3e): CCND2, CSTA and S100A14 were selected by the bioinformatic analysis described in Supplementary  Figure 8 ; while SFN, THBS1, DKK3 and LDHB displayed the most consistent previously published evidence for promoter hypermethylation in CaP and downregulation during prostate epithelial differentiation (Figure 3e and  Supplementary Table 2 ). All seven genes were consistently downregulated in luminal cells compared with basal cells in both BPH and CaP (Figure 4a ), while the DNA methylation analysis showed that they were almost never hypermethylated in basal cells from both BPH and CaP (Figure 4b) . In luminal cells, hypermethylation was either frequent in both BPH and CaP (CSTA, S100A14 and SFN), frequent only in CaP (CCND2) or rare but CaP specific in (DKK3, LDHB, THBS1). Taken together, these results show that several genes do behave similarly to GSTP1: they are consistently downregulated through differentiation in both BPH and CaP, while DNA methylation arises preferentially in luminal cells, with some genes being hypermethylated only in CaP, while others in both BPH and CaP.
Differentiation of prostate epithelial cells induces downregulation of DAH genes, promoter transcriptional inactivation, but not DNA hypermethylation. To better understand the regulation of DAH genes, we studied their behaviour in a prostate epithelial differentiation model in vitro, by culturing the cells as acinus-like spheroids in Matrigel 40 (3D conditions). To monitor differentiation, BPH-1 cells were transduced with a lentiviral vector where the expression of mOrange is under the control of PSAPb promoter, specifically activated in the later stages of prostatic differentiation 30 ( Figure 5a ). After 7 days of 3D culture, mOrange was upregulated in B50% of the spheroids (Figure 5a ). mOrange þ cells were localized in the centre of the spheroid, indicative of prototypic gland formation. 27 AR and PSA transcripts were upregulated in 3D cultures compared with standard 2D cultures ( Supplementary  Figures 9A and B) , whereas both Cytokeratin5 and GSTP1 were downregulated in the inner part of the spheroid (Supplementary Figure 9C) , confirming prostate-specific differentiation and indicating polarization of the spheroid. Figure 9C) suggesting that complete luminal differentiation was reached only in a subfraction of cells. Around 80% of the spheres also contained cells expressing activated-caspase3 in the inner part of the spheroid. These cells were Cytokeratin5 LOW and Cytokeratin8 þ , indicating that a proportion of the differentiated cells was unstable and underwent apoptosis (Supplementary Figure 10) . As previously described, 40 cell death is not essential for complete spheroid formation and is probably a limitation of the in vitro conditions of this model.
AR protein was found only in rare cells (Supplementary
Expression of all the DAH genes tested, except CCND2, was significantly reduced in 3D conditions compared with 2D (Figure 5b) , confirming that these genes are downregulated during prostate differentiation. This was accompanied by a repression of the transcriptional activity of their promoters, measured by a decrease in bound RNAPolII and a reduction of the active chromatin marks H3K4Me3 and/or H3 acetylation; while the repressive mark H3K27Me3 remained almost constant in all genes (Figures 5c-f) . However, only a very small and nonsignificant increase in DNA hypermethylation (Figure 5g ) was found, suggesting that transcriptional inactivation and chromatin rearrangements precede DNA methylation during DAH genes' downregulation.
To clarify the role of established DNA methylation patterns on DAH genes' expression, we pharmacologically inhibited DNA methylation (5-aza-2 0 deoxycytidine, 1 mM for 96 h) in P4E6 (basal) and LNCaP (luminal) cells. As expected, all DAH genes (except LDHB) were hypermethylated in LNCaP (Supplementary Figure 10A) . After treatment, all the genes showed upregulation in LNCaP (Supplementary Figure 10B) , suggesting that, once established, DNA methylation could either promote further downregulation or act as a primary repression signal. Downregulation and hypermethylation of DAH genes are not associated with tumourigenic induction of prostate epithelial cells. To understand whether the downregulation and hypermethylation of DAH genes are strictly associated with prostate tumour formation, BPH-1 cells were recombined with either normal prostate fibroblasts (NPF -inducing normal growth) or cancer-associated fibroblasts (CAFinducing tumour formation) and grafted in the renal capsule of NOD-SCID mice 41 ( Figure 6a ). BPH-1 þ CAF tumours exhibit squamous-like differentiation and do not express AR in their epithelial component. 41, 42 Both BPH-1 þ NPF and BPH-1 þ CAF grafts expressed high levels of PAP and undetectable levels of PSA (Figure 6b) , confirming partial differentiation. Expression analysis of all the DAH genes showed no differences between BPH-1 þ NPF grafts and BPH-1 þ CAF grafts (Figure 6c ), again confirming that the regulation of these genes is not linked to the malignant nature of the cells and that downregulation of DAH genes is not necessary for tumour formation. Compared with BPH-1, expression of GSTP1, CSTA, DKK3, S100A14 and SFN was upregulated in the grafts, whereas CCND2 and LDHB remained unchanged and THBS1 was downregulated (Figure 6c) , suggesting that the correct differentiation programme (prostate adenomatous-like versus squamouslike) is necessary for the downregulation of DAH genes. As expected, DNA methylation of these genes did not change between BPH-1 þ NPF and BPH-1 þ CAF grafts (Figure 6d ), while GSTP1, CSTA and S100A14 methylation was considerably lower in grafts compared with BPH-1 cells, again showing a direct correlation between methylation and expression, but no relationship to tumorigenesis.
Discussion
CpG island hypermethylation has been demonstrated in all cancer types at multiple genomic loci. Because of its early appearance and frequency, it is thought to be one of the cancer's founding alterations and thus occurs in the cancer cell of origin, potentially even before DNA mutation. In all cancers, including CaP, hypermethylation is responsible for the downregulation of tumour suppressor genes, 16 promoting both cancer development and progression. However, the mechanisms by which CpG island hypermethylation originates in cancer are still poorly understood. Here we show a direct link between tissue-specific differentiation, gene downregulation and hypermethylation in CaP. In order to dissect intra-tumour cellular heterogeneity, we have analysed primary 3D  2D  3D  2D  3D  2D  3D  2D  3D  2D  3D  2D  3D  2D  3D In this way, we identified a set of genes (DAH) frequently hypermethylated in CaP, which is primarily downregulated through tissue-specific differentiation, both in normal tissues and cancer. For these genes, we hypothesize that DNA methylation can arise only after gene downregulation and is aided by cell hyperproliferation. Moreover, downregulation and hypermethylation of these genes are not essential for either tumour development or expansion. This set of genes includes GSTP1, the most studied hypermethylated gene in CaP. According to the literature, promoter hypermethylation directly represses GSTP1 in CaP, rendering CaP cells (or precancerous cells) more susceptible to carcinogenic insults by electrophilic compounds. 22, 43, 44 However, this theory is based on findings indicating a strong correlation, but not a causal relationship, between gene downregulation and hypermethylation in CaP. In contrast, a detailed molecular analysis of GSTP1 regulation showed that gene silencing precedes de novo methylation, and that a random 'seed' of methylation is necessary for the initiation of promoter hypermethylation. 45 However, the mechanisms of the initial GSTP1 downregulation and methylation 'seeding' were not defined as yet.
Our data now clearly show that GSTP1 is primarily downregulated through epithelial differentiation in both BPH and CaP, while promoter hypermethylation arises only in differentiated (luminal) cancer cells, most likely promoted by the hyperproliferation of these cells.
We found DAH genes to be equally downregulated in luminal cells from CaP and BPH, while basal cells constitutively expressed these genes, irrespective of their origin. Moreover, DAH genes were also significantly downregulated in CaP compared with normal prostate. If we consider that hormone naive cancers are mostly composed of luminal-like cells (o1:100 basal/luminal cell ratio in CaP versus B1:1 to B1:2.7 in the benign epithelium), [6] [7] [8] 46 we can infer that the cancer-specific downregulation seen is due to differences in ratios of cell types, rather than to a cancer-cell-specific gene repression. This conclusion is also in line with recent reports showing that hypermethylation in cancer occurs more frequently in genes already repressed in normal and precancerous tissues. 47 Our data also clearly show that the small fraction of basal cancer cells continues to express high levels of DAH genes. Basal cancer cells are considered to contain the prostate cancer stem cells that can self-renew, proliferate and differentiate in luminal cancer cells. 5, [12] [13] [14] 31 In the context of a cancer cell hierarchy, we conclude that DAH genes are primarily downregulated during the differentiation of cancer stem cells into cancer luminal cells, in a DNA methylationindependent manner. As both BPH and CaP-derived luminal cells express low levels of DAH genes, it is of critical importance to understand the mechanisms inducing hypermethylation specifically in cancer. For GSTP1, we have shown that methylation arises preferentially in differentiated cells that are aberrantly proliferating, where the gene has been already downregulated, as previously hypothesized; 48 this process could also be aided by the high levels of DNMT3A found in luminal cells. In line with this, GSTP1 hypermethylation is present in a proportion of precancerous lesions (PIN), 23 where luminal cells are first observed starting to hyperproliferate. 32 However, as both the frequency and levels of hypermethylation in DAH genes are extremely variable, and as some of the DAH genes analysed have a very low frequency of hypermethylation in CaP, we can hypothesise that other (unknown) factors are required for the successful methylation of DAH genes in luminal cells.
Because of its high frequency and early onset, promoter hypermethylation is thought to be a key step in cancer development. Our results challenge this hypothesis, showing that DAH genes' methylation is lost in primary CaP xenografts, mainly composed of undifferentiated cells, and it is not induced in the BPH-1 þ CAF tumour model. This indicates that hypermethylation of DAH genes is (i) strictly linked to complete prostate luminal differentiation; (ii) not essential for the in vivo expansion of CaP cells; and (iii) not essential for induction of prostate tumour formation.
In summary, we show that DAH genes are both expressed and unmethylated in BPH and CaP basal cells, downregulated as a result of prostate epithelial differentiation, in a process involving changes in histone modifications, and hypermethylated solely in CaP luminal cells, through their hyperproliferative phenotype (Figure 7) . Overall, this is the first report to explain the causes and the dynamics of CpG island hypermethylation in CaP, where, for this specific set of genes, which represents 5% of all genes reported to be hypermethylated in CaP, promoter methylation is downstream of gene downregulation and is not a driver of gene repression.
Therefore our results clearly show that basal CaP cells do not hypermethylate DAH genes, which are detected as methylated in unfractionated CaP tissues. Although DNA hypermethylation remains an extremely important cancerspecific biomarker, currently being fully assessed in both tissues and body fluids, our results pose important questions about the development of epigenetic therapies for cancer, which do not consider the basal subpopulation of cells. Future investigations should be focused on understanding which genes are affected by aberrant epigenetic modifications in cancer stem cells as well as differentiated cells, as these could represent valuable alternative therapeutic targets for effective cancer treatment of tumours with an acknowledged poor chemotherapeutic response rate.
Material and Methods BPH and CaP tissues collection. Prostate tissues were obtained from patients undergoing TURP or radical prostatectomy at York Hospital (York, UK) and Castle Hill Hospital (Cottingham, UK) with informed patient consent and approval from the NRES Committee Yorkshire & The Humber. Tissues were sampled immediately after surgery. For TURPs, a proportion of the prostate chips was collected for analysis. For radical prostatectomies, three core needle biopsies were taken from four different sites (left base, left apex, right base, right apex) and were directed by previous pathology, imaging and palpation. Tissues were transported in RPMI-1640 with 5% FCS and 100 U/ml antibiotic/antimycotic solution at 4 1C, and processed within 6 h. BPH or CaP diagnosis was confirmed by histological examination of representative adjacent fragments. A list of the samples utilized in this study is presented in Supplementary Figure 7 Regulation of DAH genes in prostate cancer hierarchy. Schematic representation of the proposed downregulation and hypermethylation mechanism of differentiation-associated hypermethylated genes in prostate cancer Figure 1A) . To determine the purity of the populations, cells were labelled with CD24-PE (human) (#130-095-953 Miltenyi Biotec) following the manufacturer's instructions and analysed on a CyAn ADP flow cytometer (Dako Cytomation, Stockport, UK) (Supplementary Figure 1B) . CD24
À cells were plated on to type I Collagen-coated 100 mm plates (BD Biosciences, Oxford, UK) in the presence of irradiated STO feeder cells as previously described. 5, 30, 50 Primary cultures were subsequently analysed at passage 0 or 1.
Generation and maintenance of CaP xenografts. Xenografts were generated from tissue biopsies from four patients undergoing either radical prostatectomy (Y042/07) or palliative channel TURP (H016, Y019 and H027/10). Patient details are shown in Supplementary Table 3 . Tissue biopsies were engrafted subcutaneously into intact male BALB/c/RAG2
À / À gC À / À mice. Mice were supplemented with a slow release 5a-DHT tablet (Innovative Research of America) if the patient was hormone naive at the time of biopsy. Once tumours reached 1.5 cm 3 , which was considered a humane end point, the mice were killed and the tumours were either reimplanted into further mice or the tissue was digested for further experiments. To maintain the tumour xenograft as 'near-patient,' tumours were re-established from frozen cells after five passages in mice. To generate single cells from xenografts, the same method used for human CaP tissues was utilized, and endothelial and haematopoietic cells were depleted using Lineage Cell Depletion Kit, mouse (#130-090-858 Miltenyi Biotec). Then, cell populations were separated using magnetic sorting and these kits (following the manufacturer's instructions): CD24 MicroBead Kit (#130-095-951), CD44 MicroBeads (#130-095-194), CD133 MicroBead Kit (#130-050-801, all from Miltenyi Biotec).
Cell lines. A list of the cell lines used, origin and culture conditions is provided in Supplementary Table 4 . Cells were cultured at 37 1C in a humidified atmosphere with 5% CO 2 , handled under good laboratory practice conditions in defined passage windows, monthly certified free of Mycoplasma and genotyped to ensure authenticity.
Generation of BPH-1 clones. BPH-1 cells were seeded at 312, 156 or 78 cells/dish in 10 cm Petri dishes (Corning, Amsterdam, The Netherlands). After 7 days, clones were isolated using sterile cloning rings and cells were expanded until 80% confluent in a T75 flask (Corning).
Generation of BPH-1 PSAPb-mOrange cells. Lentiviral vectors for the expression of mOrange under the control of the PSAPb promoter were produced, and BPH-1 cells were infected and selected with Blasticidin 4 mg/ml as previously described. 30, 51 In vitro differentiation of BPH-1 cells. BPH-1 cells were grown in 3D cultures under differentiating conditions as previously described 40, 52, 53 with some modifications: BPH-1 cells were seeded on a 50%(v/v) Matrigel plug and cultured in KSFM with 2% FCS, 2 mM L-glutamine, 10 nM R1881 and 10 nM b-estradiol, 5 ng/ml EGF, 1 mg/ml FGF, 4% (v/v) Matrigel, in co-culture with prostate stroma derived from a patient with high Gleason grade cancer. RNA extraction and qRT-PCR analysis. RNA was extracted using the RNeasy Mini Kit (Qiagen, Manchester, UK) or RNeasy Micro Kit (Qiagen), and reverse transcribed using random hexamers and reverse transcriptase (Superscript III, Invitrogen, Life Technologies Ltd, Paisley, UK). Real-time PCR was carried out using the enzyme mix SsoFast EvaGreen Supermix (Bio-Rad, Hemel Hempstead, UK) and specific primers (Supplementary Table 5 ) in a CFX96 real-time PCR detection system. Data were analysed using the Bio-Rad CFX Manager 2.0 (Bio-Rad).
DNA extraction, bisulphite conversion and pyrosequencing methylation analysis. DNA was extracted using the DNeasy Blood & Tissue Kit (Qiagen) or classic phenol/chloroform extraction for small samples. A 100% methylated control was generated by treating RC-165N/hTERT DNA with SssI methyltransferase (New England Biolabs, Hitchin, UK) for 4 h at 37 1C. Fifty nanograms to 1 mg of DNA was bisulphite converted using the EpiTect Bisulphite Kit (Qiagen). Pyrosequencing was carried out as previously described 50 using gene-specific primers (Supplementary Table 5 and Supplementary Figure 11 for assay localization). Hypermethylation was defined as a signal higher than the average methylation þ 2 S.D. of the BPH basal population, as described in Håvik et al.
54
Chromatin Immunoprecipitation. Chromatin immunoprecipitation was performed as described. 55 In brief, the chromatin of cells grown in 2D or 3D was cross-linked using formaldehyde and sonicated with a Bioruptor UCD-200 (Diagenode, Seraing, Belgium) (five cycles of 5 min each, 30 s ON 30s OFF, at full power and 4 1C) to obtain a chromatin average size of 300-400 bp. Immunoprecipitation was carried out overnight with 2.4 mg of antibody O/N at 4 1C. Immunoprecipitated DNA was extracted by phenol/chloroform extraction using linear acrylamide (Applied Biosystems, Life Technologies Ltd) as a carrier. DNA was then analysed by qPCR as described above, using specific primers (Supplementary Table 5 and Supplementary Figure 11 for assay localization).
Immunofluorescence analysis and image analysis. Immunofluorescence was carried out on cultured cells as previously described. 29 
Lin
À /CD31 À /CD24 þ cells were spotted on a 3-aminopropyltriethoxysilanetreated glass slide before proceeding with the same protocol. Immunofluorescence on BPH-1 cells cultured in 3D was carried out as previously described. 40 A list of antibodies is presented in Supplementary Table 6 .
Western Blot analysis. Western blot analysis was performed as described. 56 Antibodies used were anti GSTP1 (HPA019779) and anti B-actin (A5316) from Sigma-Aldrich (Dorset, UK), anti DNMT3A (ab13888), DNMT3B (ab13604), DNMT1 (ab13537) and GAPDH (ab9485) from Abcam (Cambridge, UK).
Identification of 'Differentiation-Associated Hypermethylated' genes. First, a comprehensive list of 3891 unique genes reported to be hypermethylated in CaP was generated by combining publicly available data in multiple publications 39, 48, 57, 58 and the CaP section of the following databases: pubmeth.org 59 and MethCancerDB. 60 Second, a list of 1407 genes highly expressed in prostate basal cells (from both BPH and CaP) was generated by a re-analysis of the microarray data set previously published by our lab 29 (raw data available in the ArrayExpress Database, accession E-MEXP-993). In brief, raw data were reanalyzed by robust multi-array averaging (RMA) and calculated as log2 expression. Genes were selected on the basis of these criteria: (i) no significant difference (P40.05 in a student's t-test) between BPH and CaP in any of the subpopulations (CD133 þ /a 2 b 1 hi or CD133 À /a 2 b 1 low ) for all of the probes matching each gene; (ii) average log2 expression across all samples greater than 10. The intersect of these two lists generated 206 'Differentiation-Associated Hypermethylated' genes (DAH genes) potentially behaving similarly to GSTP1.
